EOLS Evolus Inc

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Evolus (EOLS - Research Report), with a price target of $15.00. The company's shares closed yesterday at $7.78.According to TipRanks, Tsao is a 3-star analyst with an average return of 1.0% and a 37.56% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Revance Therapeutics, and Daré Bioscience.Currently, the analyst consensus on Evolus is a Moderate Buy with an average price target of $15.00.See Insiders’ Hot Stocks on TipRanks >> Based on Evolus' latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $37.
https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-evolus-eols?utm_source=advfn.com&utm_medium=referral